These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9659734)

  • 21. Distribution and characterization of canine Chagas disease in Texas.
    Kjos SA; Snowden KF; Craig TM; Lewis B; Ronald N; Olson JK
    Vet Parasitol; 2008 Apr; 152(3-4):249-56. PubMed ID: 18255233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chagas' American trypanosomiasis].
    Carrada-Bravo T
    Bol Med Hosp Infant Mex; 1983 Aug; 40(8):408-16. PubMed ID: 6414489
    [No Abstract]   [Full Text] [Related]  

  • 23. Melatonin enhances pro-inflammatory cytokine levels and protects against Chagas disease.
    Santello FH; Frare EO; Caetano LC; AlonsoToldo MP; do Prado JC
    J Pineal Res; 2008 Aug; 45(1):79-85. PubMed ID: 18284549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myocardial cellular damage and the activity of the mitochondrial ATP synthase in rats infected with a Colombian strain of Trypanosoma cruzi].
    Rendón DA; Genes CM; Triana O
    Biomedica; 2007 Jan; 27 Suppl 1():40-9. PubMed ID: 18154244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct outcomes of Trypanosoma cruzi infection in hamsters are related to myocardial parasitism, cytokine/chemokine gene expression, and protein expression profile.
    Bilate AM; Teixeira PC; Ribeiro SP; Brito Td; Silva AM; Russo M; Kalil J; Cunha-Neto E
    J Infect Dis; 2008 Aug; 198(4):614-23. PubMed ID: 18598198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of cardiac myocyte-derived endothelin-1 in chagasic cardiomyopathy: molecular genetic evidence.
    Huang H; Yanagisawa M; Kisanuki YY; Jelicks LA; Chandra M; Factor SM; Wittner M; Weiss LM; Pestell RG; Shtutin V; Shirani J; Tanowitz HB
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():263S-266S. PubMed ID: 12193100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the cellular immune response in patients with the digestive and indeterminate forms of Chagas' disease.
    Ribeiro BM; Crema E; Rodrigues V
    Hum Immunol; 2008 Aug; 69(8):484-9. PubMed ID: 18582517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of cytokines (MIG, IFN-gamma, TNF-alpha, IL-4, IL-5, and IL-10) during the different evolutive phases of chagasic esophagopathy.
    Crema E; Monteiro Ide O; Gomes MG; Silva AA; Rodrigues Júnior V
    Clin Immunol; 2006 May; 119(2):213-8. PubMed ID: 16513426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokine-like substance: origin and fate in Chagas' disease a new hypothesis about the local inflammatory reaction etiopathogenesis (experimental study in white mice).
    Okumura M; Pinto PL; Takami R; Nunes EV; Guilherme CS; Oliveira Júnior OC; Gama-Rodrigues JJ; Iriya K
    Rev Hosp Clin Fac Med Sao Paulo; 1999; 54(3):73-4. PubMed ID: 10668275
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pathological anatomy of hearts from asymptomatic Chagas disease patients dying in a violent manner].
    Lopes ER; Chapadeiro E; Andrade ZA; Almeida HO; Rocha A
    Mem Inst Oswaldo Cruz; 1981; 76(2):189-97. PubMed ID: 6817025
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.
    Bustamante JM; Presti MS; Rivarola HW; Fernández AR; Enders JE; Fretes RE; Paglini-Oliva P
    Int J Antimicrob Agents; 2007 Jun; 29(6):733-7. PubMed ID: 17395432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection.
    Abel LC; Rizzo LV; Ianni B; Albuquerque F; Bacal F; Carrara D; Bocchi EA; Teixeira HC; Mady C; Kalil J; Cunha-Neto E
    J Autoimmun; 2001 Aug; 17(1):99-107. PubMed ID: 11488642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutrophil depletion exacerbates experimental Chagas' disease in BALB/c, but protects C57BL/6 mice through modulating the Th1/Th2 dichotomy in different directions.
    Chen L; Watanabe T; Watanabe H; Sendo F
    Eur J Immunol; 2001 Jan; 31(1):265-75. PubMed ID: 11265643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The choroid plexus in experimental Chagas infection in mice].
    de Queiroz AC; Castro Filho BG
    Acta Med Port; 1985 Jun; 6(6):181-2. PubMed ID: 3936341
    [No Abstract]   [Full Text] [Related]  

  • 35. Innate and acquired immunity in the pathogenesis of Chagas disease.
    Golgher D; Gazzinelli RT
    Autoimmunity; 2004 Aug; 37(5):399-409. PubMed ID: 15621564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for Chagas' disease reactivation after heart transplantation.
    Campos SV; Strabelli TM; Amato Neto V; Silva CP; Bacal F; Bocchi EA; Stolf NA
    J Heart Lung Transplant; 2008 Jun; 27(6):597-602. PubMed ID: 18503957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The peptidergic system in Chagas's disease [proceedings].
    Long RG; Albuquerque RH; Bishop AE; Polak JM; Bloom SR
    Trans R Soc Trop Med Hyg; 1980; 74(2):273-4. PubMed ID: 6770505
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chagas' disease and ischemic stroke].
    Carod-Artal FJ
    Neurologia; 2006 Apr; 21(3):135-49. PubMed ID: 16575627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy.
    Araújo-Jorge TC; Waghabi MC; Hasslocher-Moreno AM; Xavier SS; Higuchi Mde L; Keramidas M; Bailly S; Feige JJ
    J Infect Dis; 2002 Dec; 186(12):1823-8. PubMed ID: 12447769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing of expression of inflammatory mediators in skeletal muscles from mice acutely infected with the RA strain of Trypanosoma cruzi.
    Cutrullis RA; Postan M; Petray PB; Corral RS
    Pathobiology; 2009; 76(4):170-80. PubMed ID: 19571606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.